摘要
目的观察拉米夫定阻断HBsAg、HBeAg双阳性孕妇母婴传播的效果。方法将110例HBsAg、HBeAg双阳性孕妇及其婴儿,随机分为研究组和对照组。研究组70例,自孕28周起口服拉米夫定100mg,每日1次,分娩后停服。对照组40例,不口服拉米夫定。2组新生儿出生后注射乙肝免疫球蛋白(HB IG)及乙肝疫苗(HBvac)。2组新生儿出生时及7个月时采集静脉血,检测血清HBsAg、抗-HBs和HBV-DNA。结果研究组新生儿出生当日外周血HBsAg、HBV-DNA阳性率显著低于对照组(P<0.01);研究组新生儿血清抗-HBs阳性率明显高于对照组(P<0.01);研究组婴儿7个月时外周血抗-HBs阳转率显著高于对照组(P<0.01)。结论HBsAg、HBeAg双阳性孕妇使用拉米夫定,新生儿HB IG和HBvac联合注射可以阻断HBV母婴传播。
Objective To Observe the effect of Lamivudine on interdiction of Maternal - to - Child transmission for the HBsAg, HBeAg - positive pregnant women. Methods One hundred and ten cases of HBsAg, HBeAg double - positive pregnant women and infants were randomly divided into lamivudine group （70 cases） and control group （40 cases）. In lamivudine group, patients started to take lamivudine 100mg / day from the 28th week of pregnancy and ended until delivery. In control group, patients didn＇t take lamivudine. The infants from both groups vaccinated HBIG and hepatitis B. At birth and the 7th month, collect vein blood of infants from two groups, and serum HBsAg, anti - HBs and HBV - DNA were tested. Results At the birth, peripheral blood HBsAg, HBV -DNA positive rate of the study group was significantly lower than control one ; the serum anti - HBs - positive rate of study group was greatly higher than the control one ; the positive peripheral anti - HBs transfer rate of study group at the 7th months was significantly higher than the control one. Conclusion The integrated vaccination of neonatal hepatitis B immunoglobulin （HBIG） and hepatitis B （HBvac） could interdict the maternal - to - child transmission of HBV by lamivudine for HBsAg, HBeAg -positive pregnant women.
出处
《临床合理用药杂志》
2008年第1期8-9,共2页
Chinese Journal of Clinical Rational Drug Use
